Zidovudine treatment of AIDS and ARC in Denmark 1987.
In 1987, a total of 138 Danish patients (94 AIDS and 44 ARC) received treatment with zidovudine, a total observation period of 572 treatment months. 15 AIDS and 1 ARC patient died after a median of 70 days (range 2-295). In the ARC group 4 patients developed AIDS (3 Pneumocystis carinii pneumonia, 1 Kaposi's sarcoma). Among the AIDS patients 38 new opportunistic infections were reported. 24 of these opportunistic infections occurred within 6 weeks after treatment initiation. 79 patients were observed for more than 3 months, 25 of these had their daily dose zidovudine reduced, usually from 1,200 mg to 600 mg, 9 others were temporarily off drug. HIV antigen was analyzed in serum samples from 93 patients. Of these, 28 (52%) of 54 initially HIV antigen-positive became antigen-negative, 7 (18%) of 39 initially HIV antigen-negative became antigen-positive within the first 8 weeks of zidovudine treatment. In 57 patients the total count of CD4+ cells were evaluated. A significant increase in the number of CD4+ cells was observed during treatment. In nearly all patients an increase in MCV and a decrease in neutrophil count was observed. 44 of the patients received a total of 307 blood transfusions on 94 occasions and 19 (14%) patients required multiple transfusions. The mortality among the AIDS patients was significantly lower compared to historical controls. In our experience zidovudine treatment is reasonably well tolerated and the side effects are manageable.
Teglbjaerg
L L
LL
Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark.
Mathiesen
L R
LR
Søeberg
B
B
Nielsen
L
L
Thorsen
B
B
Buhl
M
M
Pedersen
C
C
Bonnevie
O
O
Nielsen
C
C
Vestergaard
B F
BF
D000386:AIDS-Related Complex / Q000188:drug therapy* / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D015704:CD4 Antigens / Q000032:analysis; D002986:Clinical Trials as Topic; D015488:HIV Antigens / Q000032:analysis; D006679:HIV Seropositivity / Q000188:drug therapy; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D015704:CD4 Antigens; D015488:HIV Antigens; D015215:Zidovudine